- Home
- PTIX vs RDHL Comparison
PTIX vs RDHL Comparison
Compare PTIX & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PTIX
- RDHL
- Stock Information
- Founded
- PTIX 1994
- RDHL 2009
- Country
- PTIX United States
- RDHL Israel
- Employees
- PTIX N/A
- RDHL N/A
- Industry
- PTIX Biotechnology: Pharmaceutical Preparations
- RDHL Biotechnology: Pharmaceutical Preparations
- Sector
- PTIX Health Care
- RDHL Health Care
- Exchange
- PTIX Nasdaq
- RDHL Nasdaq
- Market Cap
- PTIX 3.3M
- RDHL 3.8M
- IPO Year
- PTIX 2016
- RDHL N/A
- Fundamental
- Price
- PTIX $3.83
- RDHL $1.85
- Analyst Decision
- PTIX
- RDHL
- Analyst Count
- PTIX 0
- RDHL 0
- Target Price
- PTIX N/A
- RDHL N/A
- AVG Volume (30 Days)
- PTIX 210.6K
- RDHL 18.5K
- Earning Date
- PTIX 08-13-2025
- RDHL 04-10-2025
- Dividend Yield
- PTIX N/A
- RDHL N/A
- EPS Growth
- PTIX N/A
- RDHL N/A
- EPS
- PTIX N/A
- RDHL N/A
- Revenue
- PTIX N/A
- RDHL $8,042,999.00
- Revenue This Year
- PTIX N/A
- RDHL $381.91
- Revenue Next Year
- PTIX N/A
- RDHL N/A
- P/E Ratio
- PTIX N/A
- RDHL N/A
- Revenue Growth
- PTIX N/A
- RDHL 23.17
- 52 Week Low
- PTIX $2.35
- RDHL $1.71
- 52 Week High
- PTIX $15.54
- RDHL $20.28
- Technical
- Relative Strength Index (RSI)
- PTIX 53.21
- RDHL 43.03
- Support Level
- PTIX $3.55
- RDHL $1.72
- Resistance Level
- PTIX $3.97
- RDHL $2.08
- Average True Range (ATR)
- PTIX 0.23
- RDHL 0.09
- MACD
- PTIX 0.04
- RDHL 0.01
- Stochastic Oscillator
- PTIX 81.83
- RDHL 27.78
About PTIX Protagenic Therapeutics Inc.
Protagenic Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. It provides treatments for mood, anxiety, depression, and neurodegenerative disorders by using peptide-based and brain-active therapeutics. The company's main compound, PT00114, is a synthetic form of Teneurin Carboxy-terminal Associated Peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. It has also created a portfolio of novel neuropeptides that are in various stages of development and preclinical evaluation for the treatment of mood disorders.
About RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.